0001062822-26-000050
SEC filingLexicon Pharmaceuticals reported total revenues of $49.8 million for FY 2025, a 60% increase from $31.1 million in FY 2024. This growth was primarily driven by a $45 million upfront payment from the Novo Nordisk license agreement for LX9851 and $4.6 million in net product revenue from INPEFA sales. The company incurred a net loss of $50.3 million, significantly improved from a $200.4 million net loss in FY 2024, reflecting reduced operating expenses following a late-2024 restructuring. Operating expenses decreased to $98.7 million from $227.6 million in the prior year. Cash used in operations was $67.9 million, while investing activities provided $113.0 million from net maturities of investments. The company ended the year with $125.2 million in total cash, cash equivalents, short-term investments, and restricted cash, and believes its current resources are sufficient to fund operations for at least the next 12 months.
Lexicon Pharmaceuticals reported FY 2025 total revenues of $49.8 million, representing a 60% increase from $31.1 million in FY 2024. This growth was primarily driven by a $45 million upfront payment from the Novo Nordisk license agreement for LX9851 and $4.6 million in net product revenue from INPEFA sales. The company significantly reduced its net loss to $50.3 million from $200.4 million in the prior year, reflecting substantial cost reductions following a late-2024 restructuring. Operating expenses decreased 57% to $98.7 million from $227.6 million in FY 2024. Net loss per common share improved to $0.14 from $0.63 in the prior year.
Revenue composition for FY 2025 consisted of $45.0 million from the Novo Nordisk license agreement, $4.6 million from net product sales of INPEFA, and $156,000 from royalties and other revenue. This compares to FY 2024 revenues of $25.0 million from the Viatris licensing agreement and $6.0 million from INPEFA sales. The shift in revenue mix reflects the company's strategic focus on licensing arrangements while maintaining minimal commercial operations for INPEFA following its restructuring. The company noted that it has derived substantially all revenues from strategic collaborations and technology licenses, with a limited number of revenue sources.
Cost of sales was $274,000 for FY 2025, representing approximately 0.6% of total revenues. The company noted that cost of goods sold as a percentage of net product revenue will be less than 10% subsequent to utilization of remaining "zero-cost" inventory. Research and development expenses decreased 28% to $61.1 million from $84.5 million in FY 2024, primarily due to lower clinical external research expenses. Selling, general and administrative expenses decreased 74% to $37.3 million from $143.1 million, driven by reduced personnel costs, professional fees, and marketing expenses following the restructuring.
Cash used in operating activities was $67.9 million for FY 2025, primarily reflective of the net loss of $50.3 million and working capital changes. Investing activities provided $113.0 million, primarily from net maturities of investments. Financing activities used $48.5 million, mainly from debt repayments. The company ended the year with $125.2 million in total cash, cash equivalents, short-term investments, and restricted cash, including $29 million in a blocked account required by debt covenants. Total assets were $185.0 million, with total liabilities of $77.4 million and stockholders' equity of $107.5 million. Long-term debt, net was $49.4 million.
Management believes current unrestricted cash and investment balances, along with expected revenues from collaborations, will be sufficient to fund operations for at least the next 12 months. The company continues to devote resources to research and development of sotagliflozin for hypertrophic cardiomyopathy and type 1 diabetes, pilavapadin for neuropathic pain, and preclinical programs. Key risk factors include dependence on collaboration revenues, regulatory uncertainties for drug candidates, potential product liability exposure, and stock price volatility. The company noted that Invus, L.P. and its affiliates own approximately 48.3% of outstanding common stock and exert substantial control over corporate matters.